343 related articles for article (PubMed ID: 26745811)
1. Diagnostic performance of 18F-FDG PET/contrast-enhanced CT versus contrast-enhanced CT alone for post-treatment detection of ovarian malignancy.
Tawakol A; Abdelhafez YG; Osama A; Hamada E; El Refaei S
Nucl Med Commun; 2016 May; 37(5):453-60. PubMed ID: 26745811
[TBL] [Abstract][Full Text] [Related]
2. (18) F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of recurrent bone and soft tissue sarcoma.
Al-Ibraheem A; Buck AK; Benz MR; Rudert M; Beer AJ; Mansour A; Pomykala KL; Haller B; Juenger H; Scheidhauer K; Schwaiger M; Herrmann K
Cancer; 2013 Mar; 119(6):1227-34. PubMed ID: 23233156
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic value of integrated ¹⁸F-fluoro-2-deoxyglucose positron emission tomography/computed tomography in recurrent epithelial ovarian cancer: accuracy of patient selection for secondary cytoreduction in 134 patients.
Lee YJ; Kim YM; Jung PS; Lee JJ; Kim JK; Kim YT; Nam JH
J Gynecol Oncol; 2018 May; 29(3):e36. PubMed ID: 29400023
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic accuracy of (18)F-FDG PET/CT compared with that of contrast-enhanced MRI of the breast at 3 T.
Magometschnigg HF; Baltzer PA; Fueger B; Helbich TH; Karanikas G; Dubsky P; Rudas M; Weber M; Pinker K
Eur J Nucl Med Mol Imaging; 2015 Oct; 42(11):1656-1665. PubMed ID: 26121928
[TBL] [Abstract][Full Text] [Related]
5. Clinical usefulness of post-treatment FDG PET/CT in patients with ovarian malignancy.
Han EJ; Park HL; Lee YS; Park EK; Song MJ; Yoo IR; Kim SH; Choi WH
Ann Nucl Med; 2016 Nov; 30(9):600-607. PubMed ID: 27299438
[TBL] [Abstract][Full Text] [Related]
6. Role of
Dolci C; Ceppi L; Guerra L; Crivellaro C; Lamanna M; Adorni M; Elisei F; Bonazzi CM; Sina F; Fruscio R; Messa C
Int J Gynecol Cancer; 2019 Oct; 29(8):1298-1303. PubMed ID: 31366569
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic value of F-18 FDG PET/CT for local and distant disease relapse surveillance in surgically treated RCC patients: Can it aid in establishing consensus follow up strategy?
Elahmadawy MA; Elazab MSS; Ahmed S; Salama M
Nucl Med Rev Cent East Eur; 2018; 21(2):85-91. PubMed ID: 30070347
[TBL] [Abstract][Full Text] [Related]
8. Role of contrast-enhanced 18F-FDG PET/CT imaging in the diagnosis and staging of renal tumors.
Gündoğan C; Çermik TF; Erkan E; Yardimci AH; Behzatoğlu K; Tatar G; Okçu O; Toktaş MG
Nucl Med Commun; 2018 Dec; 39(12):1174-1182. PubMed ID: 30234688
[TBL] [Abstract][Full Text] [Related]
9. Assessment of combination of contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography for evaluation of ovarian masses.
Tsuboyama T; Tatsumi M; Onishi H; Nakamoto A; Kim T; Hori M; Sakane M; Hori Y; Morii E; Hatazawa J; Tomiyama N
Invest Radiol; 2014 Aug; 49(8):524-31. PubMed ID: 24637584
[TBL] [Abstract][Full Text] [Related]
10. The value of 18F-FDG PET/CT imaging combined with detection of CA125 and HE4 in the diagnosis of recurrence and metastasis of ovarian cancer.
Sun J; Cui XW; Li YS; Wang SY; Yin Q; Wang XN; Gu L
Eur Rev Med Pharmacol Sci; 2020 Jul; 24(13):7276-7283. PubMed ID: 32706065
[TBL] [Abstract][Full Text] [Related]
11. Utility of contrast-enhanced FDG-PET/CT in the clinical management of pancreatic cancer: impact on diagnosis, staging, evaluation of treatment response, and detection of recurrence.
Asagi A; Ohta K; Nasu J; Tanada M; Nadano S; Nishimura R; Teramoto N; Yamamoto K; Inoue T; Iguchi H
Pancreas; 2013 Jan; 42(1):11-9. PubMed ID: 22699206
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic value of PET/CT is similar to that of conventional MRI and even better for detecting small peritoneal implants in patients with recurrent ovarian cancer.
Sanli Y; Turkmen C; Bakir B; Iyibozkurt C; Ozel S; Has D; Yilmaz E; Topuz S; Yavuz E; Unal SN; Mudun A
Nucl Med Commun; 2012 May; 33(5):509-15. PubMed ID: 22357440
[TBL] [Abstract][Full Text] [Related]
13. Novel perioperative imaging with 18F-FDG PET/CT and intraoperative 18F-FDG detection using a handheld gamma probe in recurrent ovarian cancer.
Cohn DE; Hall NC; Povoski SP; Seamon LG; Farrar WB; Martin EW
Gynecol Oncol; 2008 Aug; 110(2):152-7. PubMed ID: 18539314
[TBL] [Abstract][Full Text] [Related]
14. Impact of positron emission tomography/computed tomography in the management of patients with epithelial ovarian carcinoma after treatment.
Nasu K; Abe W; Takai N; Tomonari K; Narahara H
Arch Gynecol Obstet; 2011 May; 283(5):1121-6. PubMed ID: 20574659
[TBL] [Abstract][Full Text] [Related]
15. Detection of loco-regional recurrence in malignant head and neck tumors: a comparison of CT, MRI, and FDG PET-CT.
Kim ES; Yoon DY; Moon JY; Baek S; Han YM; Seo YL; Yun EJ
Acta Radiol; 2019 Feb; 60(2):186-195. PubMed ID: 29754496
[TBL] [Abstract][Full Text] [Related]
16. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer.
Thrall MM; DeLoia JA; Gallion H; Avril N
Gynecol Oncol; 2007 Apr; 105(1):17-22. PubMed ID: 17208284
[TBL] [Abstract][Full Text] [Related]
17. Whole-body MRI with diffusion-weighted imaging: a valuable alternative to contrast-enhanced CT for initial staging of aggressive lymphoma.
Balbo-Mussetto A; Cirillo S; Bruna R; Gueli A; Saviolo C; Petracchini M; Fornari A; Lario CV; Gottardi D; De Crescenzo A; Tarella C
Clin Radiol; 2016 Mar; 71(3):271-9. PubMed ID: 26749081
[TBL] [Abstract][Full Text] [Related]
18. Positron Emission Tomography/Computed Tomography in Platinum-sensitive Recurrent Ovarian Cancer: A Single-center Italian Study.
Gadducci A; Simonetti E; Manca G; Guidoccio F; Fanucchi A; Cosio S; Volterrani D
Anticancer Res; 2020 Apr; 40(4):2191-2197. PubMed ID: 32234914
[TBL] [Abstract][Full Text] [Related]
19. Indirect comparison of the diagnostic performance of
Hu X; Li D; Liang Z; Liao Y; Yang L; Wang R; Wang P; Cai J
BMC Cancer; 2021 Oct; 21(1):1080. PubMed ID: 34615498
[TBL] [Abstract][Full Text] [Related]
20. Role of 18F-FDG PET/CT in diagnosing peritoneal carcinomatosis in the restaging of patient with ovarian cancer as compared to contrast enhanced CT and tumor marker Ca-125.
Rubini G; Altini C; Notaristefano A; Merenda N; Rubini D; Ianora AA; Asabella AN
Rev Esp Med Nucl Imagen Mol; 2014; 33(1):22-7. PubMed ID: 23948509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
